Liposome Drug Delivery Market is Anticipated to Witness High Growth Owing to Increase in Chronic Diseases
Liposome Drug Delivery Market |
Liposome
drug delivery involves encapsulation of drug molecules within
liposomes—spherical lipid vesicles—for targeted drug delivery and release at
the site of action. This vesicular drug delivery system improves solubility,
bioavailability, and pharmacokinetics of various drugs by encapsulating them in
an aqueous core or within the lipid bilayer. Liposomes improve drug targeting
to specific sites and provide controlled or sustained release of therapeutics.
The global liposome drug delivery market is estimated to be valued at US$ 5,482.2 Mn in 2024 and is expected
to exhibit a CAGR of 8.9% over the
forecast period 2024 to 2031.
Key Takeaways
Key players operating in the Liposome
Drug Delivery Market Demand include Gilead Sciences, Inc., Luye Pharma
Group, Ipsen Biopharmaceuticals, Inc., Pacira Pharmaceuticals, Inc., Acuitas
Therapeutics, LIPOSOMA B.V., Takeda Pharmaceutical Company Limited, Taiwan
Liposome Company, Ltd., Endo International, and Jazz Pharmaceuticals plc. These
players are focusing on developing advanced liposomal formulations of existing
drugs and expanding their pipelines by filing for regulatory approvals.
There are several opportunities in the liposome drug delivery market owing to
the rise in cancer prevalence, increasing R&D investment, and growing
demand for targeted therapeutics. Liposomes offer an excellent vehicle to deliver
chemotherapeutics, nucleic acids, and other drugs in a safe and efficient
manner to treat various cancers.
Globally, companies are expanding their footprints across key markets to
strengthen their market share. For instance, in March 2021, Endo International
received approval from Health Canada for BELBUCA liposomal buprenorphine buccal
film for managing chronic pain. This approval helped expand the drug's
commercial availability across Canada.
Market Drivers
Rise in chronic diseases such as cancer and viral infections: Liposomes provide
a highly targeted drug delivery system to deliver anticancer and antiviral
drugs efficiently to diseased sites and improve therapeutic outcomes. This is a
key factor driving their increasing adoption.
Advantages over conventional drugs: Liposomes encapsulation improves drugs'
solubility, stability, and pharmacokinetics while minimizing toxicity. This
reduces side effects and enhances patient compliance which propels the market
growth.
Market Restrains
High costs associated with R&D: Developing advanced liposomal formulations
and scaling up production involves significant investments and costs which
constraints market growth.
Segment Analysis
The liposome drug delivery market is dominated by targeted drug delivery
sub segment. Targeted drug delivery offers advantages like minimizing drug
exposure to healthy tissues and enhanced accumulation of the drug in the target
diseased cells. It reduces side effects and improves therapeutic efficacy. The
targeted drug delivery sub segment commands around 60% of the total liposome
drug delivery market share due to its advantages over conventional drug
delivery methods.
Global Analysis
North America dominates the global liposome drug delivery market with a
share of over 35% in 2024. Factors such as increasing adoption of
nanotechnology driven drug delivery systems, presence of well-established
healthcare infrastructure and high R&D investments by pharmaceutical
companies are supporting the growth. Asia Pacific is expected to witness the
fastest growth during the forecast period owing to rising healthcare
expenditure, growing incidences of cancer and infectious diseases. Rapid
economic development and improving accessibility to advanced treatment options
are strengthening the liposome drug delivery market in the emerging countries
of Asia Pacific.
Get more insights on Liposome
Drug Delivery Market
Comments
Post a Comment